Loading...

AASLD: Once-Daily HCV Protease Inhibitors Show Early Promise

553 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Nov 4, 2009

http://www.medpagetoday.com

BOSTON -- Two investigational drugs targeting the hepatitis C virus (HCV) protease enzyme helped patients clear the virus with once-daily dosing, in contrast with the three-times-per-day schedule needed for similar drugs in development.

Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/

The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/apps/de...

MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageT...
Medpage Today on Facebook: https://www.facebook.com/MedPageToday

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...